The 2024 surge in FDA approvals for aflibercept biosimilars reflects significant progress in offering cost-effective ...

The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar ...

Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while ...

The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including ...

At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence ...

In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first ...

The top 5 oncology biosimilar articles in 2024 cover Duke's recommendations for cell and gene therapy biosimilars, FDA approval of Shanghai Henlius Biotech's trastuzumab biosimilar, Boehringer ...

The top legal stories in biosimilars from 2024 emphasize the ongoing struggle between ensuring timely patient access and ...